Hualan Biological Engineering, Inc. (002007.SZ): As of July 10th, the company has more than 1.5 million investors.

As of July 10, 2024, hualan biological engineering, inc. had over 1.5 million investors on its investor interaction platform.

Gelonghui FinanceJul 12 03:08 ET

GLE Announcements Selection: Zhuhai Guanyu Plans to Invest Not More Than 2 Billion Yuan in Malaysia Guanyu New Energy Project; Zijin Mining Group: Net Income Is Expected to Increase by About 41%-50% YoY in the First Half of the Year.

Investment project: Zhuhai Guanyu (688772.SH): plans to invest no more than 2 billion yuan to build new energy projects for Guanyu batteries in Malaysia; Tianyuan Group (002386.SZ): Haifeng and Rui plan to invest 0.136 billion yuan to build an optimized ion membrane electrolysis tank project for chlor-alkali plant; Tianyuan Group (002386.SZ): Haifeng and Tai plan to invest 73.8971 million yuan in the quality improvement optimization technology transformation project for titanium dioxide; Tianyuan Group (002386.SZ): Haifeng and Rui plan to invest 72.61 million yuan to build a 40MW/80WWh user-side electrochemical energy storage power station.

Gelonghui FinanceJul 8 10:55 ET

Express News | Hualan Biological Says Chairman, Senior Execs Plan to Increase Holdings in the Company by 1.2-2.4 Mln Shares Within Six Months

ReutersJul 8 05:37 ET

Hualan Biological Engineering Inc. (SZSE:002007) Stock Goes Ex-Dividend In Just Three Days

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Hualan Biological Engineering Inc. (SZSE:002007) is about to trade ex-dividend in the next 3 d

Simply Wall StJun 9 21:39 ET

Shareholders in Hualan Biological Engineering (SZSE:002007) Are in the Red If They Invested Three Years Ago

Investing in stocks inevitably means buying into some companies that perform poorly. Long term Hualan Biological Engineering Inc. (SZSE:002007) shareholders know that all too well, since the share pr

Simply Wall StJun 7 18:29 ET

Huaxin Securities: Both the supply and demand sides of blood products continue to improve, and the scale effect of leading companies gradually emerges.

According to the research reports released by Huaxin Securities, with the support and attention of domestic policies, the planning of new plasma stations such as the "14th Five-Year Plan" will gradually be implemented, and the construction of plasma stations will accelerate. China's plasma collection scale will continue to increase. In 2023, the plasma collection volume will exceed 12079 tons, an increase of more than 18.6% compared with 2022. Blood products belong to essential pharmaceuticals, and the entire industry is a licensed business, which determines its natural high policy barrier characteristics. The scale of plasma collection, the comprehensive utilization rate of blood plasma, and the profit-making ability of blood plasma are the core factors. The scale of plasma collection directly determines the scale of the enterprise. The number of existing varieties and research products are used to determine the comprehensive utilization rate and profit-making ability of blood plasma.

Zhitong FinanceJun 7 03:23 ET